FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013282919> ?p ?o ?g. }

• W2013282919 abstract "Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 20% of the patients do not benefit from this clinical treatment and, predictive factors of response were not defined yet. This study was designed to evaluate the importance of biological markers to predict response and prognosis in stage II and III breast cancer patients treated with taxane and anthracycline combination as neoadjuvant setting.Sixty patients received preoperative docetaxel (75 mg/m2) in combination with epirubicin (50 mg/m2) in i.v. infusion in D1 every 3 weeks after incisional biopsy. They received adjuvant chemotherapy with CMF or FEC, attaining axillary status following definitive breast surgery. Clinical and pathologic response rates were measured after preoperative therapy. We evaluated the response rate to neoadjuvant chemotherapy and the prognostic significance of clinicopathological and immunohistochemical parameters (ER, PR, p51, p21 and HER-2 protein expression). The median patient age was 50.5 years with a median follow up time 48 months after the time of diagnosis.Preoperative treatment achieved clinical response in 76.6% of patients and complete pathologic response in 5%. The clinical, pathological and immunohistochemical parameters were not able to predict response to therapy and, only HER2 protein overexpression was associated with a decrease in disease free and overall survival (P = 0.0007 and P = 0.003) as shown by multivariate analysis.Immunohistochemical phenotypes were not able to predict response to neoadjuvant chemotherapy. Clinical response is inversely correlated with a risk of death in patients submitted to neoadjuvant chemotherapy and HER2 overexpression is the major prognostic factor in stage II and III breast cancer patients treated with a neoadjuvant docetaxel and epirubicin combination." @default.
• W2013282919 created "2016-06-24" @default.
• W2013282919 creator A5006084752 @default.
• W2013282919 creator A5008447927 @default.
• W2013282919 creator A5038400415 @default.
• W2013282919 creator A5049802686 @default.
• W2013282919 creator A5051554413 @default.
• W2013282919 creator A5090278499 @default.
• W2013282919 date "2007-02-26" @default.
• W2013282919 modified "2023-09-25" @default.
• W2013282919 title "HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination" @default.
• W2013282919 cites W1930298597 @default.
• W2013282919 cites W1955397179 @default.
• W2013282919 cites W1974135529 @default.
• W2013282919 cites W1992944232 @default.
• W2013282919 cites W2036294483 @default.
• W2013282919 cites W2046189140 @default.
• W2013282919 cites W2048045188 @default.
• W2013282919 cites W2050466428 @default.
• W2013282919 cites W2052151176 @default.
• W2013282919 cites W2059102920 @default.
• W2013282919 cites W2064367468 @default.
• W2013282919 cites W2066747782 @default.
• W2013282919 cites W2069548442 @default.
• W2013282919 cites W2080252511 @default.
• W2013282919 cites W2082814305 @default.
• W2013282919 cites W2086766680 @default.
• W2013282919 cites W2090099441 @default.
• W2013282919 cites W2098262535 @default.
• W2013282919 cites W2104528117 @default.
• W2013282919 cites W2113242459 @default.
• W2013282919 cites W2114840421 @default.
• W2013282919 cites W2131686669 @default.
• W2013282919 cites W2133585870 @default.
• W2013282919 cites W2135424430 @default.
• W2013282919 cites W2139510434 @default.
• W2013282919 cites W2142495011 @default.
• W2013282919 cites W2156394189 @default.
• W2013282919 cites W2156544288 @default.
• W2013282919 cites W2204696794 @default.
• W2013282919 cites W2405055043 @default.
• W2013282919 cites W4301697311 @default.
• W2013282919 doi "https://doi.org/10.1186/1471-2407-7-36" @default.
• W2013282919 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1820790" @default.
• W2013282919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17324279" @default.
• W2013282919 hasPublicationYear "2007" @default.
• W2013282919 type Work @default.
• W2013282919 sameAs 2013282919 @default.
• W2013282919 citedByCount "63" @default.
• W2013282919 countsByYear W20132829192012 @default.
• W2013282919 countsByYear W20132829192013 @default.
• W2013282919 countsByYear W20132829192014 @default.
• W2013282919 countsByYear W20132829192015 @default.
• W2013282919 countsByYear W20132829192016 @default.
• W2013282919 countsByYear W20132829192017 @default.
• W2013282919 countsByYear W20132829192018 @default.
• W2013282919 countsByYear W20132829192019 @default.
• W2013282919 countsByYear W20132829192020 @default.
• W2013282919 countsByYear W20132829192021 @default.
• W2013282919 countsByYear W20132829192022 @default.
• W2013282919 countsByYear W20132829192023 @default.
• W2013282919 crossrefType "journal-article" @default.
• W2013282919 hasAuthorship W2013282919A5006084752 @default.
• W2013282919 hasAuthorship W2013282919A5008447927 @default.
• W2013282919 hasAuthorship W2013282919A5038400415 @default.
• W2013282919 hasAuthorship W2013282919A5049802686 @default.
• W2013282919 hasAuthorship W2013282919A5051554413 @default.
• W2013282919 hasAuthorship W2013282919A5090278499 @default.
• W2013282919 hasBestOaLocation W20132829191 @default.
• W2013282919 hasConcept C121608353 @default.
• W2013282919 hasConcept C126322002 @default.
• W2013282919 hasConcept C143998085 @default.
• W2013282919 hasConcept C204232928 @default.
• W2013282919 hasConcept C2776694085 @default.
• W2013282919 hasConcept C2776802502 @default.
• W2013282919 hasConcept C2777511904 @default.
• W2013282919 hasConcept C2778292576 @default.
• W2013282919 hasConcept C2778311097 @default.
• W2013282919 hasConcept C2780140570 @default.
• W2013282919 hasConcept C2780521871 @default.
• W2013282919 hasConcept C2780835546 @default.
• W2013282919 hasConcept C2781190966 @default.
• W2013282919 hasConcept C530470458 @default.
• W2013282919 hasConcept C71924100 @default.
• W2013282919 hasConceptScore W2013282919C121608353 @default.
• W2013282919 hasConceptScore W2013282919C126322002 @default.
• W2013282919 hasConceptScore W2013282919C143998085 @default.
• W2013282919 hasConceptScore W2013282919C204232928 @default.
• W2013282919 hasConceptScore W2013282919C2776694085 @default.
• W2013282919 hasConceptScore W2013282919C2776802502 @default.
• W2013282919 hasConceptScore W2013282919C2777511904 @default.
• W2013282919 hasConceptScore W2013282919C2778292576 @default.
• W2013282919 hasConceptScore W2013282919C2778311097 @default.
• W2013282919 hasConceptScore W2013282919C2780140570 @default.
• W2013282919 hasConceptScore W2013282919C2780521871 @default.
• W2013282919 hasConceptScore W2013282919C2780835546 @default.
• W2013282919 hasConceptScore W2013282919C2781190966 @default.
• W2013282919 hasConceptScore W2013282919C530470458 @default.
• W2013282919 hasConceptScore W2013282919C71924100 @default.
• W2013282919 hasIssue "1" @default.

• next